🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Tongji Hospital, Tongji University School of Medicine clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Tongji Hospital, Tongji University School of Medicine as lead sponsor. Synced 26 Sep 2026
5Current trials
3Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Tongji Hospital, Tongji University School of Medicine is the lead sponsor of 5 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are Car-T and SsCART-19. The most-studied condition is B Cell Malignancies.

ClinicalTrials.gov trials by status

  • Recruiting360%
  • Not yet open240%

Trials by phase

  • Phase EARLY_PHASE1240%
  • Not applicable120%
  • Phase 1/2120%
  • Phase 1120%
01

Clinical trials sponsored by Shanghai Tongji Hospital, Tongji University School of Medicine

5 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
NCT06375161 · ClinicalTrials.gov ↗ · B Cell Malignancies
Phase EARLY_PHASE1 Recruiting 2023-12 China
Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients
NCT07064109 · ClinicalTrials.gov ↗ · ACS - Acute Coronary Syndrome
Not applicable Recruiting 2025-07 China
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
NCT06987916 · ClinicalTrials.gov ↗ · B Cell Lymphoma
Drug: SsCART-19
Phase 1/2 Recruiting 2025-04 China
An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors
NCT06951425 · ClinicalTrials.gov ↗ · Solid Tumors
Phase EARLY_PHASE1 Not yet open 2025-06 China
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07043218 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
Drug: Car-T
Phase 1 Not yet open 2025-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Tongji Hospital, Tongji University School of Medicine trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Tongji Hospital, Tongji University School of Medicine trials

5 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China53

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in B Cell Malignancies

SponsorTrials
Shenzhen Geno-Immune Medical Institute3

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Tongji Hospital, Tongji University School of Medicine trials

How many clinical trials does Shanghai Tongji Hospital, Tongji University School of Medicine sponsor?

Shanghai Tongji Hospital, Tongji University School of Medicine is the lead sponsor of 5 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Tongji Hospital, Tongji University School of Medicine trials recruiting?

Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Tongji Hospital, Tongji University School of Medicine testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Car-T (1) and SsCART-19 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.